1. Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, et al. Clinical Factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. Dig Dis. 2016;34(6):659–64.
2. Iwamoto T, Maeda M, Hisanaga T, Saeki I, Fujisawa K, Matsumoto T, et al. Predictors of the effect of tolvaptan on the prognosis of cirrhosis. Intern Med. 2016;55(20):2911–6.
3. Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, et al. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS One. 2017;12(3):e0174649.
4. Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, et al. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatol Res. 2016 Mar;46(3):E194–200.
5. La Villa G, Romanelli RG, Casini Raggi V, Tosti-Guerra C, De Feo ML, Marra F, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology. 1992 Jul;16(1):156–61.